US10652527B2ActiveUtilityA1

Goggle imaging systems and methods

91
Assignee: UNIV WASHINGTONPriority: Jan 23, 2012Filed: Nov 13, 2018Granted: May 12, 2020
Est. expiryJan 23, 2032(~5.5 yrs left)· nominal 20-yr term from priority
Inventors:Samuel Achilefu
A61B 2090/364A61B 90/30A61B 1/0005H04N 13/344A61K 49/0056A61B 34/25A61B 90/361G02B 27/017A61B 1/0692A61K 49/0034A61K 49/0032A61B 90/36C07K 7/06H04N 5/374H04N 25/76
91
PatentIndex Score
7
Cited by
74
References
9
Claims

Abstract

A compound of formula (I) is provided having the structure: cypate-cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH, and each amino acid is independently in a D or L configuration. Also provided are pharmaceutical compositions that include the compound of formula (I) and its use in treating cancer by administering it to a patient in need thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A compound of formula (I), or a salt thereof,
   cypate-cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH  (I)
 
 wherein each amino acid is independently in a D or L configuration. 
 
     
     
       2. The compound according to  claim 1 , wherein the cypate is 
       
         
           
           
               
               
           
         
       
     
     
       3. The compound of formula (I) according to  claim 1 , wherein at least one of the Cys amino acid residues is D-Cys. 
     
     
       4. The compound of formula (I) according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
       5. The compound of formula (I) according to  claim 1 , wherein the compound is LS-301: 
       
         
           
           
               
               
           
         
       
     
     
       6. A pharmaceutical composition comprising:
 the compound of formula (I) according to  claim 1 , or a pharmaceutically acceptable salt thereof, and 
 a pharmaceutically acceptable carrier. 
 
     
     
       7. The pharmaceutical composition according to  claim 6 , wherein said composition is in a formulation suitable for intravenous administration. 
     
     
       8. The pharmaceutical composition according to  claim 6 , wherein the compound is LS-301. 
     
     
       9. The compound of formula (I) according to  claim 1 , wherein the compound is

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.